Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28711440 | 0.79 | CDC7 (0.45) | PTGS2 | |
| SCHEMBL20025721 | 0.79 | L3MBTL1 (0.44) | KDM1A | |
| SCHEMBL20657182 | 0.79 | KDM1A (0.53) | KDM1A | |
| SCHEMBL20595214 | 0.77 | KDM1A (0.60) | KDM1APTGS2 | |
| SCHEMBL20595044 | 0.76 | KDM1A (0.51) | KDM1A | |
| SCHEMBL20595090 | 0.70 | KDM1A (0.53) | KDM1APTGS2 | |
| SCHEMBL20595084 | 0.70 | HTR6 (0.52) | — | |
| SCHEMBL12595919 | 0.69 | EPAS1 (0.46) | KDM1APTGS2PTGS1 | |
| SCHEMBL13211334 | 0.69 | EPAS1 (0.46) | KDM1APTGS2PTGS1 | |
| SCHEMBL28317016 | 0.68 | MAOA (0.35) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213396-B | Indole-2-ketone compound and preparation method and application thereof | 深圳市乐土生物医药有限公司 | 2023-03-24 | — | — | CN | disclosed |
| CN-114213396-A | Indole-2-ketone compound and preparation method and application thereof | 深圳市乐土生物医药有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3642195-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2020-04-29 | — | — | EP | disclosed |
| CN-111032641-A | Substituted 5-cyanoindole compounds and uses thereof | 诺华股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| WO-2018234978-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | KDM1A, KDM5A, KDM1B | KDM1A 1/4885PTGS2 3465/4885PTGS1 2734/4885 |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | KDM1A, KDM5A, KDM1B | KDM1A 1/4885PTGS2 3465/4885PTGS1 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.